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Assessing  pathological  changes  within  the  nucleus  ambiguus  of  horses  with  recurrent 
laryngeal neuropathy: an extreme, length-dependent axonopathy 
 
 
 
Abstract: 
 
Introduction: Equine recurrent laryngeal neuropathy (RLN) is a naturally occurring model of 
length-dependent  axonopathy  characterised  by  asymmetrical  degeneration  of  recurrent 
laryngeal nerve axons (RLn). Distal RLn degeneration is marked, however it is unclear 
whether degeneration extends to include cell bodies (consistent with a neuronopathy). 
Methods: With examiners blinded to RLN severity, brainstem location and side, we examined 
correlations between RLN severity (assessed using left distal RLn myelinated axon count) 
and histopathological features (including chromatolysis and glial responses) in the nucleus 
ambiguus cell bodies, and myelinated axon count of the right distal RLn of 16 horses. 
Results: RLN severity was not associated with RLn cell body number (p>0.05), or 
degeneration. A positive correlation between the left and right distal RLn myelinated axon 
counts was identified (R
2
=0.57, p<0.05). 
Discussion:  We  confirm  that  RLN,  a  length-dependent  distal  axonopathy,  occurs  in  the 
 
absence of detectable neuronopathy. 
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Introduction 
 
Length-dependent  axonopathies  represent  a  large  group  of  neurological  diseases 
characterised by degeneration of long (sensory and motor) nerves with genetic and acquired 
causes 
1-4
. Although these examples of length-dependent axonopathies have diverse 
aetiologies, it has been hypothesised that many of them share similar pathogeneses, such as 
axonal transport deficits, cytoskeletal dysfunction or metabolic imbalances that are ultimately 
catastrophic to these axons due to their extreme length
5
. Large animal models are crucial for 
the development of effective treatment options, as they recapitulate the length of the affected 
nerves. Indeed, large animal models of human disease are increasingly recognised as 
important, as significant differences become apparent between human diseases and their 
rodent models
6
. 
Equine RLN is an asymmetrical, primarily distal axonopathy affecting the recurrent 
laryngeal nerves (RLn) (left more so than the right). These nerves are the longest motor 
nerves in the horse (in tall horses the left RLn can be 2.5m in length and it is up to 30cm 
longer than the right RLn
7
). The disease is characterised by neurogenic atrophy and paresis of 
the intrinsic laryngeal muscles
8, 9
. Despite the prevalence of RLN being as high as 42%,
10 
its 
aetiopathogenesis is unknown; environmental and genetic factors likely interplay to produce 
the RLN-phenotype
11-13
. 
 
There  is  extensive  characterisation  of  peripheral  nerve  and  muscle  pathology  in 
RLN
14, 15 
but the presence or absence of an associated neuronopathy (i.e. a cell body reaction) 
within the nucleus ambiguus (which comprises the RLn’s axonal cell bodies, see 
Supplementary Figure 1), is questionable 
16-18
. In the few studies examining an accompanying 
 
 
 
 
 
presence of neuronopathy in RLN, there were no detectable associated somal reactions or 
apparent loss of cell bodies within the nucleus ambiguus
16-18
. However, these investigations 
were hampered by unblinded analyses, possible phenotyping inaccuracies (a single 
laryngoscopic examination used to grade RLN severity
14, 19
) and un-matched control groups 
In humans, distal axonopathies without associated cell body reactions primarily target 
the   axon  and   include  certain  chemotherapy-induced  (microtubule  targeting  drugs)
20
, 
diabetic
21 
and immune-mediated neuropathies (e.g. with hepatitis C virus whereby immune- 
mediated  axonal  destruction  is  a  sequel  to  infection)
22
.  In  contrast,  neurodegenerative 
diseases that result in both axon and cell body loss, such as amyotrophic lateral sclerosis 
(ALS), commonly result from the toxic effects of mutant protein aggregation or from 
mutations within genes that affect cell body health
23, 24
. Thus, if RLN could be definitely 
shown to be a distal axonopathy either with or without a neuronopathy then its application as 
a  large  animal  model  of  human  disease  could  be  substantially  supported  whilst  also 
benefitting   affected   horses   by   advancing   the   understanding   of   possible   underlying 
aetiologies. 
Here  we  investigate  the  central  nervous  system  involvement  in  this  equine 
neurological condition with a view to promoting its application in  length-dependent motor 
axonopathy research. We investigated two hypotheses: (1) Horses with a more severe RLN 
phenotype (i.e low myelinated axon count in the left recurrent laryngeal nerve) show 
degeneration and have fewer cell bodies in their nuclei ambigui compared to horses with a 
less severe RLN phenotype and (2) these changes will be more pronounced in the left nucleus 
ambiguus compared to the right. 
 
 
 
 
 
 
 
 
Methods 
 
Subjects 
 
Tissues were collected from 16 thoroughbred/warmblood-type male horses; all were greater 
than 5 years of age and had a wither height exceeding 166cm. The brainstem and distal left 
and right RLns (within 10cm of the larynx) were harvested from all horses. Twelve horses 
were obtained from an abattoir and the remaining 4, were euthanized whilst under general 
anaesthesia as part of a concurrent RLN study. The study was approved by the College’s 
Clinical Research Ethical Review Board (2015 1381). 
 
 
 
Tissue Preparation, Fixation and Sectioning 
 
Each brainstem was placed in 4% buffered paraformaldehyde (PFA) for a minimum of 7 days 
and then cut transversely into four 4mm segments, due to the diffuse nature of the nucleus 
ambiguus: 1) 8mm rostral to the obex (R8), 2) 4mm rostral to the obex (R4), 3) at the level of 
the obex (R0) and 4) 4mm caudal to the obex (C4)
25
. The brainstem was placed with its 
rostral aspect downwards (furthest from the lid) into a fixation cassette ready for processing, 
with a tissue marker on the right dorsal aspect. Following processing, serial 4μm (10μm for 
the Luxol Fast Blue stained sections) sections were obtained and stored at room temperature 
prior to staining. 
Following the brainstem acquisition, larynges were harvested and 2-3cm sections of 
both right and left recurrent laryngeal nerves were removed immediately caudal to the larynx. 
A distal sampling site was selected as this demonstrates the greatest pathological changes 
 
 
 
 
 
when examining nerves by light microscopy
8, 26-30
. The nerves were secured at physiological 
length on a piece of cardboard to straighten the nerve fibres and the proximal end of each 
nerve marked. The nerves were fixed in 10% buffered PFA for approximately 2 months. 
After fixation, nerves were processed to resin as previously described
31
. Semi-thin sections 
(1µm) were cut with glass knives on an ultramicrotome (Leica OMU4) and mounted on glass 
slides. 
 
 
 
Histology 
 
The localisation of each nucleus ambiguus was performed based upon its position relative to 
other anatomical landmarks. Briefly, the large polygonal cell bodies of the RLns are located 
in the ventrolateral medulla oblongata with their highest density being found approximately 
8mm rostral and caudal to the obex
25, 32
. The nuclei’s borders include: axially, the radices of 
 
cranial nerve XII; abaxially, the nucleus of the spinal tract of cranial nerve V; ventrally, the 
lateral reticular nucleus and dorsally, the vagal nerve fibres
25, 32 
(Supplementary Figure 1). 
Specific stains were chosen to identify common pathological features (recorded on a 
continuous scale of how many cell body profiles were affected or as a dichotomous result) 
associated with central nervous system degeneration
33
; cell body profile numbers, 
chromatolysis, nuclear margination or fragmentation, a shrunken or swollen cell body profile, 
presence  of  axonal  spheroids,  vacuolation  (present  or  absent),  inclusion  bodies, 
demyelination or a glial response (present or absent) were all assessed. Sequential brainstem 
sections were stained with hematoxylin and eosin (H&E), luxol fast blue (LFB), and cresyl 
violet (CV); astrocytes were identified by immunohistochemical labelling of glial fibrillary 
 
 
 
 
 
acidic protein (GFAP)
34
. Slides were first dewaxed in xylene for at least 20 minutes at room 
temperature, before being rehydrated through a graded series of alcohols (100%, 100%, 90%, 
and 70%) and finally placed in Tris-buffered saline (TBS) for 5 minutes, and then treated 
with 3% hydrogen peroxide (in methanol) for 15 minutes, at room temperature, before being 
rinsed in TBS. Blocking with 10% goat serum in TBS was performed, for 60 minutes. The 
serum   was   removed   and   the   primary   antibody   (1:200)   (GFAP   Ab190288   (mouse 
monoclonal) Abcam, UK) diluted in TBS was applied, and incubated overnight at 4
0
C. A no- 
primary-antibody negative control was included in each batch. Three washes with TBS 
followed, before the application of the biotin-conjugated secondary antibody (1:500) (goat 
anti-mouse  antibody  I1903-25T-USB  Stratech  Scientific  Labs)  for  1  hour  at  room 
temperature before another wash. Streptavidin (Vectastain Elite ABC Peroxidase Kit, Vector 
Labs) was diluted according to the manufacturer’s instructions and applied to the slides for 30 
minutes  at  room  temperature,  followed  by  washing.  DAB  (3,3  diaminobenzadine)  was 
applied to each slide for 5 minutes at room temperature, then washed with distilled water, and 
the sections dehydrated through a graded series of ethanols. Lastly the slides were placed in 
xylene for 10 minutes, and the coverslip applied using DPX (DPX Mountant for histology 
06522, Sigma-Aldrich, UK). All staining was performed in sets with each brainstem level for 
every horse stained simultaneously to reduce any batch-effect when analyzing the sections. 
Semithin sections of the RLns were stained with 1% methylene blue (in distilled water) as 
previously described 
35
. 
 
 
 
Image Analysis 
 
 
 
 
 
Each slide was digitalised using a commercial service (IQPath Laboratory Digitalisation 
Service, UCL, UK). The cell bodies within the nucleus ambiguus were identified in each 
section (or recorded as absent), as described above, and an image captured of both the left 
and right-sided nuclei separately. These images were then assigned a random number to blind 
the horse number and side from the examiner. The number of cell bodies within the nucleus 
ambiguus were recorded per region, per side in all H&E images. 
 
 
 
Recurrent Laryngeal Nerve Myelinated Axon Counts 
 
Images of every fascicle for the entire transversely sectioned left and right RLn were captured 
at 40x magnification (Nikon Eclipse 50i microscope with a Leica camera), with the examiner 
blinded to the side and horse. For each nerve fascicle the total number of myelinated axons 
was automatically counted using a custom designed programme in Volocity 6.0 (PerkinElmir, 
NY, U.S.A). The myelinated axon count for the left RLn for each horse was used to estimate 
the RLN severity; i.e. horses with a lower myelinated axon count were considered to have 
more severe RLN. 
 
 
 
Statistical Analysis 
 
The total number of cell body profiles in the left nucleus ambiguus compared to the right was 
analysed using a two-tailed paired T-test. Differences in the total number of cell bodies 
present at each region, between each region and between each side (left and right nucleus 
ambiguus) were investigated using a two-way repeated measures ANOVA, with post-hoc 
(Tukey’s)  testing.  The  associations  between  the  number  of  cell  body  profiles  and  the 
 
 
 
 
 
pathological features recorded, in every region for both sides and RLN severity was assessed 
by linear regression. All analyses were performed in the statistical package R, and differences 
were considered statistically significant when p<0.05. 
 
 
 
 
 
 
 
Results 
 
Ratio of Left to Right Myelinated Axon Counts in the Recurrent Laryngeal Nerve 
 
There was a statistically significant, and strong relationship between the myelinated axon 
counts in the left and right recurrent laryngeal nerves, such that as the axon count in the left 
nerve decreased so did the count in the right (n=14) (R
2
=0.57; p=0.001) (Supplementary 
Figure 2). 
 
 
 
Cell Body Numbers 
 
The nucleus ambiguus could be identified in all horses (n=16), where tissue was present for 
that region. There was no significant difference between the number of cell bodies counted 
between the left and right nucleus ambiguus at any region, nor when the regional data was 
grouped (Figure 1) independent of RLN severity. 
 
 
 
RLN Severity 
 
RLN severity was not associated with any of the following, for any region on either the left or 
right side: number of cell bodies, chromatolysis, nuclear margination or fragmentation, 
shrunken cell body profile, swollen cell body profile, axonal spheroids, vacuolation, inclusion 
bodies, demyelination (Figure 3), glial response, or astrocytosis (GFAP) (Supplementary 
Table 1). Indeed, no vacuolation, inclusion bodies, or demyelination were identified in any 
horse. Examples of a typical cell body within the nucleus ambiguus (H&E and CV) and 
astrocytosis are presented in Figures 2 and 4. 
 
 
 
 
 
Discussion 
 
Here we showed a lack of detectable degeneration within or loss of RLn cell bodies, 
in either the left or right sides, of horses with RLN. However, it is possible that horses might 
not have been sampled during a period of active neurodegeneration. Cell body chromatolysis 
(cytoplasmic eosinophilia, loss of Nissl substance, pyknosis and eventual karyorrhexis), 
reactive astrocytosis, and microgliosis are the histopathological hallmarks of active 
neurodegeneration
36
. In rodent models, chromatolysis occurs within 48 hours of an axonal 
insult and lasts for 15-20 days; at this point, the cell body can regenerate if the insult has 
stopped or it will eventually die (taking up to 80 additional days
33
). With the latter scenario 
leading to a reduction in cell body numbers and, potentially the generation of a glial scar. 
Despite the chronic severe axonal pathology present in some of our cases, there was no 
evidence of glial scarring, and no association between RLN severity and cell body counts was 
detected; this suggests that axonal degeneration-mediated neuronal pathology is not a feature 
of RLN. Consequently, from our data we reject both hypotheses: RLN severity was not 
associated with cell body degeneration, reduced cell body numbers or demyelination in the 
central nervous system. 
Our findings - that RLN is not associated with the RLn cell body degeneration - 
recapitulates the findings of other authors
17, 18, 25
, and presents the novel result that RLN 
severity is also not associated with a reduction in nucleus ambiguus cell body number. Whilst 
the cell bodies associated with cranial nerves IX and XI can contribute to the cell body 
profiles identified in the NA, within the horse, these nerves’ cell bodies cluster at the rostral 
and caudal regions of the NA (>8mm rostral to and >6mm caudal to the obex)
25 
rather than 
 
 
 
 
 
the majority of regions analysed here, such that we believe they had limited contribution to 
the cell body profiles numbers recorded. Our data is derived from a large sample size, 
ensuring the results were free from bias (blinding) and by using a continuous scale for RLN 
severity to phenotype individuals that prevents misclassification of disease status: when using 
laryngoscopy to phenotype horses for RLN, daily variations in applied grades can cause 
horses to be classified as a control, subclinical or clinical cases incorrectly
19
. Further, the 
 
extensive fibre type grouping that occurs in intrinsic laryngeal muscles supplied by diseased 
RLns in affected horses, very likely means that clinical phenotyping (using for example, 
resting or exercising laryngoscopy) is inaccurate
14
. 
RLN can now be classified as a distal axonopathy, without an associated degeneration 
of the cell bodies of the RLns
14
. The advantage of a more specific classification is that it 
focuses the list of likely aetiological mechanisms. In humans, distal axonopathies without the 
presence of a neuronopathy are seen in some forms of chemotherapy-induced neuropathy 
(those targeting microtubules), diabetic neuropathies (specifically distal symmetrical 
polyneuropathy and small fibre neuropathy), and immune-mediated axonopathies (typically 
occurring secondarily to infectious conditions (e.g. HIV or Campylobacter)
20-22, 37
. In these 
disorders, the predilection for axonal degeneration over other neuronal components is caused 
by diverse, but likely interrelated, perturbations to axonal transportation
38
, mitochondrial 
functionality
39
, oxidative homeostasis
40
, oxygen delivery
41 
and immune-mediated axonal 
destruction
42,   43
.  In  chemotherapy-induced  neuropathies,  microtubule-destabilizing  drugs 
cause dismantling of the axonal cytoskeleton, which prevents normal axonal transportation
38
. 
This,  in  turn,  reduces  shuttling  of  neurotrophins,  and  hinders  removal  of  aged  or 
 
 
 
 
 
dysfunctional mitochondria, potentially leading to increases in oxidative stress and reduced 
ATP production. Axonal transportation deficits are associated with paranodal evaginations 
seen by electron microscopy in RLn sections of RLN-affected horses
44
. Ischaemic lesions
28
 
and an infectious aetiology
45 
have also been proposed by authors to cause RLN; further, the 
 
potential mechanisms underlying these diseases might be mirrored in human diabetic 
neuropathies (in which hyperglycaemia and ischaemia are postulated to induce the 
axonopathy) or immune-mediated neuropathies (in which neuronal proteins are targeted by 
the patient’s own immune system). 
Some authors have speculated that chemotherapy-induced neuropathy and diabetic 
neuropathies cause distal axonopathy via a final common pathway, in which Wallerian 
degeneration occurs in the distal axon, but the cell body is spared
37
. Wallerian degeneration is 
the process of systematic dismantling of an axon distal to the site of injury, via calpain 
activation, that results from increased axonal calcium influx, ultimately leading to orderly 
degradation of the cytoskeleton and membrane proteins
46
. The exact components of this 
common pathway have not been fully unravelled, however crucial events include the 
activation of the protein SARM1, and down-regulation of the NAD+ generating enzyme 
NMNAT2
47-49
. The overexpression of NMNAT2, in an experimental Wallerian degeneration 
model, delays axonal degeneration
50, 51
. These could be important proteins to investigate in 
 
the aetiopathogenesis of RLN, and other length-dependent axonopathies of humans. 
 
The presence of reactive astrocytes in this study, in the absence of clear 
neuropathological changes, likely reflects regional differences in the binding of the GFAP 
antibody. This might reflect true differences in astrocyte activation, but can occur because of 
 
 
 
 
 
fixation artefacts
52
. If true acute astrocytosis was present, other indicators of inflammation 
should have been detectable and reactive astrocytes in the form of gemistocytes might have 
been identified
53
. This increase in GFAP staining was not associated with RLN severity and 
thus its overall significance is unknown. 
A finding in this study was the positive correlation between the left and right RLn 
myelinated  axon  counts.  This  suggests  that  degeneration  of  the  left  and  right  nerve 
myelinated axons occurs simultaneously, albeit to a greater extent in the left nerve. The ratio 
of  the  left:right  myelinated  axon  counts  were  less  than  1  in  all  individuals  (n=14), 
highlighting that the left sided degeneration is most prominent even in mildly affected horses. 
This supports the bilateral nature of this disease process
8, 18, 26, 30, 54
. Similar, but less severe 
 
signs of this distal axonopathy have been reported to occur in the right distal nerve in RLN- 
affected horses with one author commenting that the degree of pathology seen in the distal 
right nerve [in severe RLN cases] is similar to that in the proximal left nerve
26
. 
The main assumption applied to this data is that the proportion of myelinated axons 
between the left and right RLns in horses is typically similar. In 9 young horses (<2 years old 
and lacking neurogenic atrophy of the laryngeal muscles) the total myelinated axon counts in 
the left and right distal RLns were approximately equal
27
. However, the myelinated fibre 
density (fibres/mm
2
) of the distal left nerve was less than that of the distal right nerve in 
horses with subclinical RLN
54
. In line with the clinical signs of RLN being confined to the 
left side only, the axonal loss in this study was always more severe in the left nerve compared 
to the right: the lowest myelinated axon count being 27 in the left nerve, and correspondingly, 
 
 
 
 
 
552 in the right. This further suggests that although both nerves degenerate distally, the right 
is less severely affected, likely because of its shorter length
7
. 
In conclusion, this research has confirmed that RLN occurs without evidence of cell 
body degeneration and has revealed an association between left and right RLn myelinated 
axon counts. Length-dependent axonopathies are often hard to recapitulate in rodent models: 
this study, and others before it, confirm that this naturally-occurring, length-dependent 
axonopathy of horses might be a very useful, and highly prevalent model of related diseases 
in humans. Future work should be directed at examining the pathophysiology of the disorder, 
to determine mechanisms that are shared with length-dependent axonopathies of other species 
in the hope of establishing new therapeutics for these disorders. 
 
 
 
 
 
 
 
 
Abbreviations: 
 
 
ALS Amyotrophic Lateral Sclerosis 
CMT Charcot Marie Tooth disease 
CV Cresyl Violet staining 
GFAP Glial fibrillary acidic protein 
H&E Haematoxylin and Eosin staining 
LFB Luxol Fast Blue staining 
NMNAT2 Nicotinamide mononucleotide adenyltransferase 2 
 
RLN Recurrent Laryngeal Neuropathy 
 
RLn Recurrent laryngeal nerve 
 
SARM1 Sterile alpha and TIR motif-containing protein 1 
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Figure 1 A) Number of cell body profiles in the nucleus ambiguus, in each brainstem region, 
on the left and right side; B) Mean grouped number of cell body profiles counted within the 
nucleus ambiguus on the left and right sides of the brainstem with error bars depicting the 
standard deviation. Despite the mean number of cell body profiles on the left being lower 
than their right counterparts, the difference did not reach statistical significance (p=0.28). 
Box plots show median, interquartile range and range. 
 
 
 
Figure 2 A) Cell bodies of neurons within the left nucleus ambiguus of a horse, sectioned at 
the obex (H&E). These are typical large, polygonal neurons (black arrow) seen within the 
nucleus ambiguus with an obvious clear (euchromatic) nucleus containing a prominent, single 
nucleolus (black dotted arrow). The neuronal cytoplasm has a mildly speckled appearance 
due to the large number of ribosomes or Nissl’s granules present. The surrounding neuropil 
(blue dotted arrow) contains axons, oligodendrocytes, astrocytes, microglia and vasculature. 
The small nuclei of oligodendrocytes are scattered throughout the neuropil. Black scale bar = 
144µm. B) Cell bodies of neurons in the right nucleus ambiguus at the level of the obex, in 
the horse (Cresyl Violet). The cytoplasm of the large polygonal cell body profiles stains 
brightly   blue,   highlighting   Nissl’s   granules   (ribosomes).   There   is   no   evidence   of 
chromatolysis in this section. Black scale bar = 137µm. 
 
 
 
Figure 3 Luxol Fast Blue staining of the brainstem at a level 8mm rostral to the obex in a 
horse. Lipoproteins are stained blue, such that areas of demyelination would appear pale. No 
demyelination was found in this study. The location of the nucleus ambiguus on each side is 
 
 
 
 
 
highlighted (black circle). The left side of the brainstem is located on the left of the figure. 
Black scale bar represents 3118µm. 
 
 
 
 
Figure 4 Immunolabelling for GFAP of astrocytes within the nucleus ambiguus of a horse, 
 
4mm rostral to the obex. The two images are of the left (A) and right (B) nucleus ambiguus 
from the same horse (mild RLN severity), showing the presence of more reactive astrocytes 
in the right side within this individual horse. The presence of the reactive astrocytes was not 
accompanied by any signs of neuronal degeneration, nor correlated with RLN severity and so 
the significance is unknown. Reactive astrocytes were seen with near equal frequency in the 
left and right nucleus ambiguus, amongst the horses included in this research. The black bar 
represents 140µm. 
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